Protagonist Therapeutics, Inc. (PTGX)

NASDAQ: PTGX · Real-Time Price · USD
54.44
+0.76 (1.42%)
At close: Jun 25, 2025, 4:00 PM
54.61
+0.17 (0.31%)
After-hours: Jun 25, 2025, 6:19 PM EDT

Protagonist Therapeutics Stock Forecast

Stock Price Forecast

The 9 analysts that cover Protagonist Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $67.11, which forecasts a 23.27% increase in the stock price over the next year. The lowest target is $51 and the highest is $80.

Price Target: $67.11 (+23.27%)
Analyst Consensus: Strong Buy
Target Low Average Median High
Price $51 $67.11 $70 $80
Change -6.32% +23.27% +28.58% +46.95%

Analyst Ratings

The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Jan '25Feb '25Mar '25Apr '25May '25Jun '25
Strong Buy 444445
Buy 444444
Hold 000000
Sell 000000
Strong Sell 000000
Total 888889

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Citigroup
Citigroup
Strong Buy
Initiates
$72
Strong Buy Initiates $72 +32.26% Jun 17, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$80
Strong Buy Reiterates $80 +46.95% Jun 3, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$80
Strong Buy Reiterates $80 +46.95% May 19, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$80
Strong Buy Reiterates $80 +46.95% Apr 10, 2025
Wedbush
Wedbush
Buy
Reiterates
$70
Buy Reiterates $70 +28.58% Mar 28, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
83.56M
from 434.43M
Decreased by -80.77%
Revenue Next Year
122.95M
from 83.56M
Increased by 47.15%
EPS This Year
-1.98
from 4.23
EPS Next Year
-1.83
from -1.98
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
28.63M27.36M26.58M60.00M434.43M83.56M122.95M218.25M
Revenue Growth
12,293.07%-4.44%-2.84%125.73%624.06%-80.77%47.15%77.51%
EPS
-1.92-2.71-2.60-1.394.23-1.98-1.83-1.13
EPS Growth
--------
Forward PE
--------
No. Analysts
-----12129
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 266.1M 302.4M 711.9M
Avg 83.6M 123.0M 218.3M
Low 27.7M 19.6M 46.1M

Revenue Growth

Revenue Growth 20252026202720282029
High
-38.8%
261.9%
479.0%
Avg
-80.8%
47.1%
77.5%
Low
-93.6%
-76.5%
-62.5%

EPS Forecast

EPS 20252026202720282029
High -1.23 -0.58 -0.17
Avg -1.98 -1.83 -1.13
Low -2.47 -3.64 -2.18

EPS Growth

EPS Growth 20252026202720282029
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.